KNSA vs RHI · P/E 53, rev $677.6M vs P/E 21, rev $5.38B
Kiniksa Pharmaceuticals Ltd (KNSA) versus Robert Half International Inc (RHI) — a side-by-side from cached financials, not a winner call.
Kiniksa Pharmaceuticals Ltd (KNSA) is a drug manufacturers - specialty & generic company listed on US.
Robert Half International Inc (RHI) is a staffing & employment services company listed on US.
Latest reported KNSA revenue for 2025-12-31 was $677.6M. Net income was $59.0M. Revenue was up 60.1% from 2024-12-31 to 2025-12-31. KNSA currently screens at market cap $3.73B and trailing P/E 53.2.
Latest reported RHI revenue for 2025-12-31 was $5.38B. Net income was $133.0M. RHI currently screens at market cap $4.38B and trailing P/E 21.4.
KNSA currently screens at market cap $3.73B and trailing P/E 53.2. RHI currently screens at market cap $4.38B and trailing P/E 21.4.
Not investment advice. Open the KNSA and RHI stock pages for the full models.
Not investment advice.